Symbio Pharmaceuticals Limited ((JP:4582)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SymBio Pharmaceuticals Limited is conducting a multi-center, global, open-label Phase 1b/2 clinical study titled ‘A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma As Well As to Evaluate the Safety and Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Using The Recommended Phase 2 Dose.’ The study aims to assess the safety, tolerability, and preliminary efficacy of Brincidofovir in patients with relapsed or refractory lymphoma, including Extranodal Natural Killer/T-cell Lymphoma.
The intervention being tested is Brincidofovir, an experimental drug administered twice weekly via intravenous infusion. It is intended to determine the optimal dosage and evaluate its safety and efficacy in treating the specified conditions.
The study follows an interventional design with a sequential intervention model and no masking. Its primary purpose is treatment-focused, aiming to establish the recommended Phase 2 dose of Brincidofovir through dose escalation in Phase 1b and subsequent treatment in Phase 2.
The study began on December 24, 2024, with the last update submitted on June 12, 2025. These dates are crucial as they mark the study’s initiation and the latest information available, reflecting ongoing progress.
This clinical study update could influence SymBio Pharmaceuticals’ stock performance by potentially boosting investor confidence if the results are positive. The study’s success may also impact the competitive landscape in the oncology sector, particularly concerning treatments for relapsed or refractory lymphoma.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.